Company Overview - Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases [2] - The company was founded in 2014 and is headquartered in Boston, Massachusetts [2] - Compass's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth [2] Product Pipeline - The company is developing a pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective antitumor response [2] - Key strategies include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance [2] - Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data [2] Upcoming Investor Events - Compass Therapeutics will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 11:00am ET in New York, NY [1] - The company will also attend the Cantor Global Healthcare Conference on September 17, 2024, at 8:35am ET, also in New York, NY [1] - Presentations from these events will be archived for 90 days on Compass's Events page [1]

Group 1 - Compass Pathways plc is a biotechnology company focused on mental health innovation, particularly through its proprietary psilocybin treatment, COMP360, which has received Breakthrough Therapy designation from the FDA and ILAP designation in the UK for treatment-resistant depression [2][3] - The company has initiated a phase 3 clinical program for COMP360 psilocybin treatment in treatment-resistant depression, marking it as the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted [3] - Previous studies, including a phase 2b study, demonstrated a statistically significant improvement in depressive symptom severity after three weeks for patients receiving a single 25mg dose of COMP360 with psychological support [3] Group 2 - Compass Pathways will participate in several investor conferences in September 2024, including the Morgan Stanley 22nd Annual Global Healthcare Conference, H. C. Wainwright 26th Annual Global Investment Conference, and Cantor Global Healthcare Conference, with live audio webcasts available [1] - The company is headquartered in London, UK, with additional offices in New York and San Francisco, and aims to promote mental wellbeing globally [4]

THE HO F E I 11 # Justin Paget The whole market is volatile right now, but one industry that is going through tremendous changes on multiple fronts is the real estate industry. Despite the potential benefit from declining interest rate expectations (mortgage rates have been dropping over the past few weeks, owing in large part to expectations of Fed rate cuts amid a possible U.S. recession), the industry is still watching and waiting to see what will happen once new rules from the NAR lawsuit settlement, al ...

WESTPORT, Conn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, announced today that Stephen Keller has been appointed as the Company's Chief Financial Officer (CFO), effective August 31, 2024. He will be replacing Ryan Faulkingham, who has served as the Company's CFO since July 2013 and is departing the Company effective August 30, 2024. Mr. Faulkingham will continue to serve in an advisory capacity in order to fac ...

WESTPORT, Conn., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Altor Solutions ("Altor"), a subsidiary of Compass Diversified (NYSE: CODI) and a leading designer and manufacturer of custom protective and coldchain packaging solutions for the industrial and life sciences markets, today announced it has entered into a definitive agreement to acquire Lifoam Industries, LLC ("Lifoam"), a manufacturer and distributor of temperature-controlled shipping solutions, for an enterprise value of $137 million in cash at closing (ex ...

Company Overview - Compass, Inc. is the largest residential real estate company in the United States by sales volume, founded in 2012 and based in New York City [3][4] - The company provides an end-to-end platform that empowers residential real estate agents with cloud-based software for various functions including customer relationship management and marketing [3] Upcoming Event - CEO Robert Reffkin will participate in Oppenheimer's 27th Annual Technology, Internet & Communications Conference on August 13, 2024, alongside CFO Kalani Reelitz and Chief Accounting Officer Scott Wahlers [1][2] - The event will include one-on-one meetings and a fireside chat at 11:35 AM ET, which will be accessible via a public webcast [2]

BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinicalstage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Wedbush PacGrow Healthcare Conference taking place in New York City, New York on Tuesday, August 13, 2024, at 11 AM ET. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical ...

Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million Conference call August 1 at 8:00 am ET (1:00 pm UK) LONDON and NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental he ...

Compass, Inc. (COMP) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 300%. A quarter ago, it was expected that this company would post a loss of $0.20 per share when it actually produced a loss of $0.27, delivering a surprise of -35%. Over the last four quarters, the company has surpasse ...

WESTPORT, Conn., July 31, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, announced today its consolidated operating results for the three months ended June 30, 2024. "I'm pleased to announce another strong quarter with results that exceeded our expectations, driven by continued strength in our consumer businesses," said Elias Sabo, CEO of Compass Diversified. "While Q2 saw deteriorating economic conditions that negatively im ...